Clinical trialNCT06957080Active, not recruitingPhase 2/PHASE3Interventional

A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

SponsorEyeBiotech Ltd.Enrollment1,054Diabetic Macular Edema (DME)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME). In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be entered in the study.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Charles Miller, MD PhD
EyeBiotech Ltd.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

164 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Cordoba, Argentina
Córdoba, Argentina
Cordoba, Argentina
Córdoba, Argentina
Salta, Argentina
Salta, Argentina
Salta, Argentina
Salta, Argentina
Santa Fe, Argentina
Santa Fe, Argentina

Brazil

Aparecida de Goiania, Brazil
Aparecida de Goiânia, Brazil
Aparecida de Goiania, Brazil
Aparecida de Goiânia, Brazil
Assis, Brazil
Assis, Brazil
Belo Horizonte, Brazil
Belo Horizonte, Brazil
Blumenau, Brazil
Blumenau, Brazil
Porto Alegre, Brazil
Porto Alegre, Brazil
Sorocaba, Brazil
Sorocaba, Brazil
Sao Paulo, Brazil
São Paulo, Brazil
Sao Paulo, Brazil
São Paulo, Brazil
Vitoria, Brazil
Vitória, Brazil

Colombia

Barranquilla, Colombia
Barranquilla, Colombia
Bogata, Colombia
Bogotá, Colombia
Cali, Colombia
Cali, Colombia
Medelin, Colombia
Medellín, Colombia
Medellin, Colombia
Medellín, Colombia

Japan

Nagoya City, Japan
Nagoya, Aichi-ken, Japan
Hirosaki, Japan
Hirosaki, Aomori, Japan
Sakura, Japan
Sakura, Chiba, Japan
Yoshida-Gun, Japan
Yoshida-gun, Fukui, Japan
Fukuoka-Shi, Japan
Fukuoka, Fukuoka, Japan
Kurume City, Japan
Kurume, Fukuoka, Japan
Fukuoka-Shi, Japan
Fukuoka, Higashi-ku Fukuoka, Japan
Asahikawa, Japan
Asahikawa, Hokkaido, Japan
Amagasaki, Japan
Amagasaki, Hyōgo, Japan
Mito, Japan
Mito, Ibaraki, Japan
Kita-Gun, Japan
Kita-gun, Kagawa-ken, Japan

124 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ranibizumab →Remigromig

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 16 Apr 2025
Primary completion: 11 Jan 2027
Completion: 11 Jan 2028
Last update posted: 30 Oct 2026
Registered enrollment: 1,054
Registry id: NCT06957080

Cross-registrations

EU-CTR / CTIS (EudraCT)2025-520809-12-00jRCT/UMIN (Japan)jRCT2071250032

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.